FYI… awaiting Sedar publishing to complete Rundown. Not a good Q.
Pluses and Minuses:
Gross Adult Use revenue QoQ +$3 million or +8% (Note: excise tax increase $1 million QoQ, which, given medical is flat, is likely attributable to adult use. This would reduce the adult use revenue by $1 million or +$ 2million)
Distribution revenue QoQ +$4 million or + 7%
Wellness revenue QoQ increases $1.5 million or + 10%
Net Revenue QoQ declines $10 million or -6%
Net cannabis revenue QoQ (all segments) -$1.3 million or -2%
International cannabis revenue QoQ decreases $2 million or -11%
Alcohol, despite Breckenridge for full Q, decreases $4 million or -19%
Gross Margin negative as $47.5 million in cannabis inventory and $7.5 million in distribution inventory was impaired.
SGA (remember … last Q they ran an insurance claim credit from CC Pharma through SGA of $5 million) increased $7.5 million QoQ.
aEBITDA (my figure) was $4 million or +$1.4 million QoQ
Impairment of Long-term assets of $378 million. Attributable to rationalization of production assets given Hexo working agreement.
Ads Blocker Detected!!!
We have detected that you are using extensions to block ads. Please support us by disabling your ad blocker.